{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:51:58Z","timestamp":1788781918450,"version":"build-2803163510"},"reference-count":18,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,5,23]],"date-time":"2018-05-23T00:00:00Z","timestamp":1527033600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000226","name":"Ontario Ministry of Health and Long-Term Care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012665","name":"Institute for Clinical Evaluative Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004203","name":"Ontario Institute for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004203","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013873","name":"Government of Ontario","doi-asserted-by":"publisher","award":["-035"],"award-info":[{"award-number":["-035"]}],"id":[{"id":"10.13039\/100013873","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["MOP 137022"],"award-info":[{"award-number":["MOP 137022"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.clon.2018.05.005","type":"journal-article","created":{"date-parts":[[2018,6,28]],"date-time":"2018-06-28T13:44:06Z","timestamp":1530193446000},"page":"609-617","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["A Population-based Study of Survival Impact of New Targeted and Immune-based Therapies for Metastatic or Unresectable Melanoma"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3228-6042","authenticated-orcid":false,"given":"T.P.","family":"Hanna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Baetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.M.","family":"Booth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Eisenhauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.clon.2018.05.005_bib1","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"New Engl J Med"},{"issue":"17","key":"10.1016\/j.clon.2018.05.005_bib2","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.clon.2018.05.005_bib3","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1200\/JCO.2014.56.6018","article-title":"Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial","volume":"33","author":"Maio","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"26","key":"10.1016\/j.clon.2018.05.005_bib4","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"New Engl J Med"},{"issue":"9","key":"10.1016\/j.clon.2018.05.005_bib5","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","article-title":"Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial","volume":"17","author":"Ascierto","year":"2016","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.clon.2018.05.005_bib6","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1200\/JCO.2012.42.1529","article-title":"Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma","volume":"31","author":"Flaherty","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.clon.2018.05.005_bib7","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1200\/JCO.1999.17.9.2745","article-title":"Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma","volume":"17","author":"Chapman","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.clon.2018.05.005_bib8","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1200\/JCO.1994.12.4.806","article-title":"Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma","volume":"12","author":"Bajetta","year":"1994","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl.","key":"10.1016\/j.clon.2018.05.005_bib9","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival analysis of KEYNOTE-006","volume":"34","author":"Schachter","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.clon.2018.05.005_bib10","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1470-2045(16)30126-7","article-title":"Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial","volume":"17","author":"Weber","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2018.05.005_bib11","series-title":"Overall survival (OS) results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-na\u00efve patients with advanced melanoma (CheckMate 067)","author":"Larkin","year":"2017"},{"key":"10.1016\/j.clon.2018.05.005_bib12","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ejca.2016.11.021","article-title":"Dutch Melanoma Treatment Registry: quality assurance in the care of patients with metastatic melanoma in the Netherlands","volume":"72","author":"Jochems","year":"2017","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1016\/j.clon.2018.05.005_bib13","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1185\/03007995.2013.820693","article-title":"French investigators of the MELODY Study. Treatment patterns and outcomes in patients with advanced melanoma in France","volume":"29","author":"Bedane","year":"2013","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"10.1016\/j.clon.2018.05.005_bib14","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1002\/cam4.717","article-title":"Real-world treatment practice in patients with advanced melanoma in the era before ipilimumab: results from the IMAGE study","volume":"5","author":"Middleton","year":"2016","journal-title":"Cancer Med"},{"issue":"95","key":"10.1016\/j.clon.2018.05.005_bib15","first-page":"246","article-title":"Cancer registration in Ontario: a computer approach","author":"Clarke","year":"1991","journal-title":"IARC Sci Publ"},{"key":"10.1016\/j.clon.2018.05.005_bib16","unstructured":"Kralj B. Measuring rurality - RIO2008 BASIC: methodology and results. OMA Economics Department. Available at: www.eriestclairlhin.on.ca\/Page.aspx?id=11606. [Accessed 9 June 2018]."},{"issue":"4","key":"10.1016\/j.clon.2018.05.005_bib17","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"New Engl J Med"},{"issue":"1","key":"10.1016\/j.clon.2018.05.005_bib18","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/CMR.0000000000000394","article-title":"Survival trends among patients with metastatic melanoma in the pretargeted and the post-targeted era: a US population-based study","volume":"28","author":"Uprety","year":"2018","journal-title":"Melanoma Res"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655518302759?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655518302759?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:44:54Z","timestamp":1760543094000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655518302759"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":18,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S0936655518302759"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2018.05.005","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Population-based Study of Survival Impact of New Targeted and Immune-based Therapies for Metastatic or Unresectable Melanoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2018.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Ltd on behalf of The Royal College of Radiologists.","name":"copyright","label":"Copyright"}]}}